Loading...

CSL Limited

CSL.AXASX
HealthcareBiotechnology
$235.14
$-4.17(-1.74%)

CSL Limited (CSL.AX) Stock Overview

Explore CSL Limited’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-24.99%
24.99%
Profit Growth
$5.70
20.81%
EPS Growth
$5.70
20.95%
Operating Margin
20.83%
57.73%
ROE
15.37%
20.81%
Dividend Yield
0.00%
21.65%
Analyst Recommendations data is not available for CSL.AXAnalyst Recommendations details for CSL.AX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

CEO

Dr. Paul F. McKenzie Ph.D.

Employees

32,698

Headquarters

45 Poplar Road, Parkville, VIC

Founded

1994

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.